Keith T. Flaherty, MD
The American Association for Cancer Research (AACR) recently announced the appointment of Keith T. Flaherty, MD, as Editor-in-Chief of Clinical Cancer Research.
Dr. Flaherty is Director of the Termeer Center for Targeted Therapies and Director of Clinical Research at the Massachusetts General Hospital Cancer Center, where he was named the Richard Saltonstall Endowed Chair in Oncology and Professor of Medicine at Harvard Medical School. He officially began his tenure as Editor-in-Chief on January 1, 2017.
“I am thrilled to take on this role at a time when the opportunities to advance science through methodologically rigorous clinical investigation are at an all-time high,” Dr. Flaherty said. “I benefit greatly from having served under Dr. Ken Anderson’s visionary leadership of the journal for the past 6 years as a senior editor.”
Dr. Flaherty is an active member of the AACR. He has been a senior editor of Clinical Cancer Research, with oversight of the melanoma section of the journal since 2010, as well as a scientific editorial board member of Cancer Discovery since its inception.
Research Focus
Dr. Flaherty’s research focuses on the understanding of the molecular and clinical consequences of inhibiting oncogenes and oncogenic pathways in melanoma while establishing individual therapeutic approaches and constructing rational combinatorial therapies. A pioneer in developing targeted therapies matched to the genetic characteristics of a patient’s tumor, Dr. Flaherty led early clinical trials on the development of vemurafenib (Zelboraf) and trametinib (Mekinist) as well as the combination of dabrafenib (Tafinlar) and trametinib.
Dr. Flaherty is also Deputy Chair for Biomarker Sciences and Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group; a scientific advisory committee member for the Melanoma Research Foundation; and President of the Society for Melanoma Research. ■
